Skip to main content
SpringerLink
Log in

Progress on early diagnosing Alzheimer’s disease

  • Review
  • Published:
Frontiers of Medicine Aims and scope Submit manuscript

Abstract

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that affects both cognition and non-cognition functions. The disease follows a continuum, starting with preclinical stages, progressing to mild cognitive and behavioral impairment, ultimately leading to dementia. Early detection of AD is crucial for better diagnosis and more effective treatment. However, the current AD diagnostic tests of biomarkers using cerebrospinal fluid and/or brain imaging are invasive or expensive, and mostly are still not able to detect early disease state. Consequently, there is an urgent need to develop new diagnostic techniques with higher sensitivity and specificity during the preclinical stages of AD. Various non-cognitive manifestations, including behavioral abnormalities, sleep disturbances, sensory dysfunctions, and physical changes, have been observed in the preclinical AD stage before occurrence of notable cognitive decline. Recent research advances have identified several biofluid biomarkers as early indicators of AD. This review focuses on these non-cognitive changes and newly discovered biomarkers in AD, specifically addressing the preclinical stages of the disease. Furthermore, it is of importance to explore the potential for developing a predictive system or network to forecast disease onset and progression at the early stage of AD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Doroszkiewicz J, Groblewska M, Mroczko B. Molecular biomarkers and their implications for the early diagnosis of selected neurodegenerative diseases. Int J Mol Sci 2022; 23(9): 4610

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Hu S, Yang C, Luo H. Current trends in blood biomarker detection and imaging for Alzheimer’s disease. Biosens Bioelectron 2022; 210: 114278

    Article  CAS  PubMed  Google Scholar 

  3. No authors listed. Alzheimer disease. Nat Rev Dis Primers 2021; 7(1): 34

  4. Gunes S, Aizawa Y, Sugashi T, Sugimoto M, Rodrigues PP. Biomarkers for Alzheimer’s disease in the current state: a narrative review. Int J Mol Sci 2022; 23(9): 4962

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Gatchel JR. Late-life depression and Alzheimer’s disease pathology: an ounce of prevention, a pound of cure. Am J Geriatr Psychiatry 2021; 29(5): 458–461

    Article  PubMed  Google Scholar 

  6. Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, Wessels AM, Shcherbinin S, Wang H, Monkul Nery ES, Collins EC, Solomon P, Salloway S, Apostolova LG, Hansson O, Ritchie C, Brooks DA, Mintun M, Skovronsky DM; TRAILBLAZER-ALZ 2 Investigators. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 2023; 330(6): 512–527

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S, Froelich L, Katayama S, Sabbagh M, Vellas B, Watson D, Dhadda S, Irizarry M, Kramer LD, Iwatsubo T. Lecanemab in early Alzheimer’s disease. N Engl J Med 2023; 388(1): 9–21

    Article  CAS  PubMed  Google Scholar 

  8. Hameed S, Fuh JL, Senanarong V, Ebenezer EGM, Looi I, Dominguez JC, Park KW, Karanam AK, Simon O. Role of fluid biomarkers and PET imaging in early diagnosis and its clinical implication in the management of Alzheimer’s disease. J Alzheimers Dis Rep 2020; 4(1): 21–37

    Article  PubMed  PubMed Central  Google Scholar 

  9. Hawksworth J, Fernández E, Gevaert K. A new generation of AD biomarkers: 2019 to 2021. Ageing Res Rev 2022; 79: 101654

    Article  CAS  PubMed  Google Scholar 

  10. Dulewicz M, Kulczyńska-Przybik A, Mroczko P, Kornhuber J, Lewczuk P, Mroczko B. Biomarkers for the diagnosis of Alzheimer’s disease in clinical practice: the role of CSF biomarkers during the evolution of diagnostic criteria. Int J Mol Sci 2022; 23(15): 8598

    Article  PubMed  PubMed Central  Google Scholar 

  11. Creese B, Ismail Z. Mild behavioral impairment: measurement and clinical correlates of a novel marker of preclinical Alzheimer’s disease. Alzheimers Res Ther 2022; 14(1): 2

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Masters MC, Morris JC, Roe CM. “Noncognitive” symptoms of early Alzheimer disease: a longitudinal analysis. Neurology 2015; 84(6): 617–622

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Hudon C, Escudier F, De Roy J, Croteau J, Cross N, Dang-Vu TT, Zomahoun HTV, Grenier S, Gagnon JF, Parent A, Bruneau MA, Belleville S; Consortium for the Early Identification of Alzheimer’s Disease–Quebec. Behavioral and psychological symptoms that predict cognitive decline or impairment in cognitively normal middle-aged or older adults: a meta-analysis. Neuropsychol Rev 2020; 30(4): 558–579

    Article  PubMed  Google Scholar 

  14. Huang YL, Lin CH, Tsai TH, Huang CH, Li JL, Chen LK, Li CH, Tsai TF, Wang PN. Discovery of a metabolic signature predisposing high risk patients with mild cognitive impairment to converting to Alzheimer’s disease. Int J Mol Sci 2021; 22(20): 10903

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Porsteinsson AP, Isaacson RS, Knox S, Sabbagh MN, Rubino I. Diagnosis of early Alzheimer’s disease: clinical practice in 2021. J Prev Alzheimers Dis 2021; 8(3): 371–386

    CAS  PubMed  Google Scholar 

  16. Montero-Odasso M, Pieruccini-Faria F, Ismail Z, Li K, Lim A, Phillips N, Kamkar N, Sarquis-Adamson Y, Speechley M, Theou O, Verghese J, Wallace L, Camicioli R. CCCDTD5 recommendations on early non cognitive markers of dementia: a Canadian consensus. Alzheimers Dement (N Y) 2020; 6(1): e12068

    Article  PubMed  Google Scholar 

  17. Frisoni GB, Boccardi M, Barkhof F, Blennow K, Cappa S, Chiotis K, Démonet JF, Garibotto V, Giannakopoulos P, Gietl A, Hansson O, Herholz K, Jack CRJr, Nobili F, Nordberg A, Snyder HM, Ten Kate M, Varrone A, Albanese E, Becker S, Bossuyt P, Carrillo MC, Cerami C, Dubois B, Gallo V, Giacobini E, Gold G, Hurst S, Lönneborg A, Lovblad KO, Mattsson N, Molinuevo JL, Monsch AU, Mosimann U, Padovani A, Picco A, Porteri C, Ratib O, Saint-Aubert L, Scerri C, Scheltens P, Schott JM, Sonni I, Teipel S, Vineis P, Visser PJ, Yasui Y, Winblad B. Strategic roadmap for an early diagnosis of Alzheimer’s disease based on biomarkers. Lancet Neurol 2017; 16(8): 661–676

    Article  PubMed  Google Scholar 

  18. Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, Bakardjian H, Benali H, Bertram L, Blennow K, Broich K, Cavedo E, Crutch S, Dartigues JF, Duyckaerts C, Epelbaum S, Frisoni GB, Gauthier S, Genthon R, Gouw AA, Habert MO, Holtzman DM, Kivipelto M, Lista S, Molinuevo JL, O’Bryant SE, Rabinovici GD, Rowe C, Salloway S, Schneider LS, Sperling R, Teichmann M, Carrillo MC, Cummings J, Jack CRJr; Proceedings of the Meeting of the International Working Group (IWG) and the American Alzheimer’s Association on “The Preclinical State of AD”; July 23, 2015; Washington DC, USA. Preclinical Alzheimer’s disease: definition, natural history, and diagnostic criteria. Alzheimers Dement 2016; 12(3): 292–323

    Article  PubMed  Google Scholar 

  19. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984; 34(7): 939–944

    Article  CAS  PubMed  Google Scholar 

  20. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O’brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007; 6(8): 734–746

    Article  PubMed  Google Scholar 

  21. Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, Delacourte A, Frisoni G, Fox NC, Galasko D, Gauthier S, Hampel H, Jicha GA, Meguro K, O’Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Sarazin M, de Souza LC, Stern Y, Visser PJ, Scheltens P. Revising the definition of Alzheimer’s disease: a new lexicon. Lancet Neurol 2010; 9(11): 1118–1127

    Article  PubMed  Google Scholar 

  22. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CRJr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7(3): 263–269

    Article  PubMed  Google Scholar 

  23. Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, DeKosky ST, Gauthier S, Selkoe D, Bateman R, Cappa S, Crutch S, Engelborghs S, Frisoni GB, Fox NC, Galasko D, Habert MO, Jicha GA, Nordberg A, Pasquier F, Rabinovici G, Robert P, Rowe C, Salloway S, Sarazin M, Epelbaum S, de Souza LC, Vellas B, Visser PJ, Schneider L, Stern Y, Scheltens P, Cummings JL. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol 2014; 13(6): 614–629

    Article  PubMed  Google Scholar 

  24. Jack CRJr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, Rowe CC, Scheltens P, Siemers E, Snyder HM, Sperling R; Contributors. NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement 2018; 14(4): 535–562

    Article  PubMed  Google Scholar 

  25. Kang JH, Korecka M, Lee EB, Cousins KAQ, Tropea TF, Chen-Plotkin AA, Irwin DJ, Wolk D, Brylska M, Wan Y, Shaw LM. Alzheimer disease biomarkers: moving from CSF to plasma for reliable detection of amyloid and tau pathology. Clin Chem 2023; 69(11): 1247–1259

    Article  PubMed  PubMed Central  Google Scholar 

  26. NIA-AA Revised Diagnostic Criteria: A Biological Definition of Alzheimer’s Disease. 2023

  27. Cheung CY, Ran AR, Wang S, Chan VTT, Sham K, Hilal S, Venketasubramanian N, Cheng CY, Sabanayagam C, Tham YC, Schmetterer L, McKay GJ, Williams MA, Wong A, Au LWC, Lu Z, Yam JC, Tham CC, Chen JJ, Dumitrascu OM, Heng PA, Kwok TCY, Mok VCT, Milea D, Chen CL, Wong TY. A deep learning model for detection of Alzheimer’s disease based on retinal photographs: a retrospective, multicentre case-control study. Lancet Digit Health 2022; 4(11): e806–e815

    Article  CAS  PubMed  Google Scholar 

  28. Zhou Y, Chia MA, Wagner SK, Ayhan MS, Williamson DJ, Struyven RR, Liu T, Xu M, Lozano MG, Woodward-Court P, Kihara Y; UK Biobank Eye & Vision Consortium; Altmann A, Lee AY, Topol EJ, Denniston AK, Alexander DC, Keane PA. A foundation model for generalizable disease detection from retinal images. Nature 2023; 622(7981): 156–163

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Agbavor F, Liang H. Predicting dementia from spontaneous speech using large language models. PLOS Digit Health 2022; 1(12): e0000168

    Article  PubMed  PubMed Central  Google Scholar 

  30. Kales HC, Lyketsos CG, Miller EM, Ballard C. Management of behavioral and psychological symptoms in people with Alzheimer’s disease: an international Delphi consensus. Int Psychogeriatr 2019; 31(1): 83–90

    Article  PubMed  Google Scholar 

  31. Jost BC, Grossberg GT. The evolution of psychiatric symptoms in Alzheimer’s disease: a natural history study. J Am Geriatr Soc 1996; 44(9): 1078–1081

    Article  CAS  PubMed  Google Scholar 

  32. Wise EA, Rosenberg PB, Lyketsos CG, Leoutsakos JM. Time course of neuropsychiatric symptoms and cognitive diagnosis in National Alzheimer’s Coordinating Centers volunteers. Alzheimers Dement (Amst) 2019; 11(1): 333–339

    Article  PubMed  Google Scholar 

  33. Nedelec T, Couvy-Duchesne B, Monnet F, Daly T, Ansart M, Gantzer L, Lekens B, Epelbaum S, Dufouil C, Durrleman S. Identifying health conditions associated with Alzheimer’s disease up to 15 years before diagnosis: an agnostic study of French and British health records. Lancet Digit Health 2022; 4(3): e169–e178

    Article  CAS  PubMed  Google Scholar 

  34. Liao Y, Xing Q, Li Q, Zhang J, Pan R, Yuan Z. Astrocytes in depression and Alzheimer’s disease. Front Med 2021; 15(6): 829–841

    Article  PubMed  Google Scholar 

  35. Desai R, Whitfield T, Said G, John A, Saunders R, Marchant NL, Stott J, Charlesworth G. Affective symptoms and risk of progression to mild cognitive impairment or dementia in subjective cognitive decline: a systematic review and meta-analysis. Ageing Res Rev 2021; 71: 101419

    Article  PubMed  Google Scholar 

  36. Geda YE, Roberts RO, Mielke MM, Knopman DS, Christianson TJH, Pankratz VS, Boeve BF, Sochor O, Tangalos EG, Petersen RC, Rocca WA. Baseline neuropsychiatric symptoms and the risk of incident mild cognitive impairment: a population-based study. Am J Psychiatry 2014; 171(5): 572–581

    Article  PubMed  PubMed Central  Google Scholar 

  37. Liew TM. Neuropsychiatric symptoms in early stage of Alzheimer’s and non-Alzheimer’s dementia, and the risk of progression to severe dementia. Age Ageing 2021; 50(5): 1709–1718

    Article  PubMed  PubMed Central  Google Scholar 

  38. Garre-Olmo J, López-Pousa S, Vilalta-Franch J, de Gracia Blanco M, Vilarrasa AB. Grouping and trajectories of neuropsychiatric symptoms in patients with Alzheimer’s disease. Part II: two-year patient trajectories. J Alzheimers Dis 2010; 22(4): 1169–1180

    PubMed  Google Scholar 

  39. Wang X, Wang R, Li J. Influence of sleep disruption on protein accumulation in neurodegenerative diseases. Ageing Neur Dis 2022; 2: 4

    CAS  Google Scholar 

  40. Shi L, Chen SJ, Ma MY, Bao YP, Han Y, Wang YM, Shi J, Vitiello MV, Lu L. Sleep disturbances increase the risk of dementia: a systematic review and meta-analysis. Sleep Med Rev 2018; 40: 4–16

    Article  PubMed  Google Scholar 

  41. Lysen TS, Luik AI, Ikram MK, Tiemeier H, Ikram MA. Actigraphy-estimated sleep and 24-hour activity rhythms and the risk of dementia. Alzheimers Dement 2020; 16(9): 1259–1267

    Article  PubMed  Google Scholar 

  42. Zhang F, Zhong R, Li S, Fu Z, Wang R, Wang T, Huang Z, Le W. Alteration in sleep architecture and electroencephalogram as an early sign of Alzheimer’s disease preceding the disease pathology and cognitive decline. Alzheimers Dement 2019; 15(4): 590–597

    Article  PubMed  Google Scholar 

  43. Sabia S, Fayosse A, Dumurgier J, van Hees VT, Paquet C, Sommerlad A, Kivimäki M, Dugravot A, Singh-Manoux A. Association of sleep duration in middle and old age with incidence of dementia. Nat Commun 2021; 12(1): 2289

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Pulver RL, Kronberg E, Medenblik LM, Kheyfets VO, Ramos AR, Holtzman DM, Morris JC, Toedebusch CD, Sillau SH, Bettcher BM, Lucey BP, McConnell BV. Mapping sleep’s oscillatory events as a biomarker of Alzheimer’s disease. Alzheimers Dement 2024; 20(1): 301–315

    Article  CAS  PubMed  Google Scholar 

  45. Zhou JN, Liu RY, Kamphorst W, Hofman MA, Swaab DF. Early neuropathological Alzheimer’s changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels. J Pineal Res 2003; 35(2): 125–130

    Article  CAS  PubMed  Google Scholar 

  46. Spinedi E, Cardinali DP. Neuroendocrine-metabolic dysfunction and sleep disturbances in neurodegenerative disorders: focus on Alzheimer’s disease and melatonin. Neuroendocrinology 2019; 108(4): 354–364

    Article  CAS  PubMed  Google Scholar 

  47. Reed NS, Oh ES. New insights into sensory impairment and dementia risk. JAMA Netw Open 2022; 5(5): e2210740

    Article  PubMed  Google Scholar 

  48. Powell DS, Oh ES, Reed NS, Lin FR, Deal JA. Hearing loss and cognition: what we know and where we need to go. Front Aging Neurosci 2022; 13: 769405

    Article  PubMed  PubMed Central  Google Scholar 

  49. Murphy C. Olfactory and other sensory impairments in Alzheimer disease. Nat Rev Neurol 2019; 15(1): 11–24

    Article  CAS  PubMed  Google Scholar 

  50. Fischer ME, Cruickshanks KJ, Schubert CR, Pinto AA, Carlsson CM, Klein BEK, Klein R, Tweed TS. Age-related sensory impairments and risk of cognitive impairment. J Am Geriatr Soc 2016; 64(10): 1981–1987

    Article  PubMed  PubMed Central  Google Scholar 

  51. Pacyna RR, Han SD, Wroblewski KE, McClintock MK, Pinto JM. Rapid olfactory decline during aging predicts dementia and GMV loss in AD brain regions. Alzheimers Dement 2023; 19(4): 1479–1490

    Article  CAS  PubMed  Google Scholar 

  52. Tahmasebi R, Zehetmayer S, Pusswald G, Kovacs G, Stögmann E, Lehrner J. Identification of odors, faces, cities and naming of objects in patients with subjective cognitive decline, mild cognitive impairment and Alzheimer’s disease: a longitudinal study. Int Psychogeriatr 2019; 31(4): 537–549

    Article  CAS  PubMed  Google Scholar 

  53. Roberts RO, Christianson TJ, Kremers WK, Mielke MM, Machulda MM, Vassilaki M, Alhurani RE, Geda YE, Knopman DS, Petersen RC. Association between olfactory dysfunction and amnestic mild cognitive impairment and Alzheimer disease dementia. JAMA Neurol 2016; 73(1): 93–101

    Article  PubMed  PubMed Central  Google Scholar 

  54. Ge YJ, Xu W, Ou YN, Qu Y, Ma YH, Huang YY, Shen XN, Chen SD, Tan L, Zhao QH, Yu JT. Retinal biomarkers in Alzheimer’s disease and mild cognitive impairment: a systematic review and meta-analysis. Ageing Res Rev 2021; 69: 101361

    Article  CAS  PubMed  Google Scholar 

  55. van de Kreeke JA, Nguyen HT, Konijnenberg E, Tomassen J, den Braber A, Ten Kate M, Yaqub M, van Berckel B, Lammertsma AA, Boomsma DI, Tan HS, Visser PJ, Verbraak FD. Longitudinal retinal layer changes in preclinical Alzheimer’s disease. Acta Ophthalmol 2021; 99(5): 538–544

    Article  CAS  PubMed  Google Scholar 

  56. O’Bryhim BE, Apte RS, Kung N, Coble D, Van Stavern GP. Association of preclinical Alzheimer disease with optical coherence tomographic angiography findings. JAMA Ophthalmol 2018; 136(11): 1242–1248

    Article  PubMed  PubMed Central  Google Scholar 

  57. O’Bryhim BE, Lin JB, Van Stavern GP, Apte RS. OCT angiography findings in preclinical Alzheimer’s disease: 3-year follow-up. Ophthalmology 2021; 128(10): 1489–1491

    Article  PubMed  Google Scholar 

  58. Dinet V, Arouche-Delaperche L, Dégardin J, Naud MC, Picaud S, Krantic S. Concomitant retinal alterations in neuronal activity and TNFα pathway are detectable during the pre-symptomatic stage in a mouse model of Alzheimer’s disease. Cells 2022; 11(10): 1650

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Villemagne VL, Chételat G. Neuroimaging biomarkers in Alzheimer’s disease and other dementias. Ageing Res Rev 2016; 30: 4–16

    Article  PubMed  Google Scholar 

  60. Nag S, Miranda-Azpiazu P, Jia Z, Datta P, Arakawa R, Moein MM, Yang Z, Tu Y, Lemoine L, Ågren H, Nordberg A, Långström B, Halldin C. Development of 11C-labeled ASEM analogues for the detection of neuronal nicotinic acetylcholine receptors (α7-nAChR). ACS Chem Neurosci 2022; 13(3): 352–362

    Article  CAS  PubMed  Google Scholar 

  61. Fontana IC, Kumar A, Nordberg A. The role of astrocytic α7 nicotinic acetylcholine receptors in Alzheimer disease. Nat Rev Neurol 2023; 19(5): 278–288

    Article  PubMed  Google Scholar 

  62. Pascoal TA, Therriault J, Benedet AL, Savard M, Lussier FZ, Chamoun M, Tissot C, Qureshi MNI, Kang MS, Mathotaarachchi S, Stevenson J, Hopewell R, Massarweh G, Soucy JP, Gauthier S, Rosa-Neto P. 18F-MK-6240 PET for early and late detection of neurofibrillary tangles. Brain 2020; 143(9): 2818–2830

    Article  PubMed  Google Scholar 

  63. Swinford CG, Risacher SL, Charil A, Schwarz AJ, Saykin AJ. Memory concerns in the early Alzheimer’s disease prodrome: regional association with tau deposition. Alzheimers Dement (Amst) 2018; 10(1): 322–331

    Article  PubMed  Google Scholar 

  64. Quan L, Moreno-Gonzalez I, Xie Z, Gamez N, Vegas-Gomez L, Song Q, Gu J, Lin W, Gomez-Gutierrez R, Wu T. A near-infrared probe for detecting and interposing amyloid beta oligomerization in early Alzheimer’s disease. Alzheimers Dement 2023; 19(2): 456–466

    Article  CAS  PubMed  Google Scholar 

  65. Montal V, Barroeta I, Bejanin A, Pegueroles J, Carmona-Iragui M, Altuna M, Benejam B, Videla L, Fernández S, Padilla C, Aranha MR, Iulita MF, Vidal-Piñeiro D, Alcolea D, Blesa R, Lleó A, Fortea J; Down Alzheimer Barcelona Neuroimaging Initiative. Metabolite signature of Alzheimer’s disease in adults with Down syndrome. Ann Neurol 2021; 90(3): 407–416

    Article  CAS  PubMed  Google Scholar 

  66. Stevenson JS, Clifton L, Kuźma E, Littlejohns TJ. Speech-innoise hearing impairment is associated with an increased risk of incident dementia in 82,039 UK Biobank participants. Alzheimers Dement 2022; 18(3): 445–456

    Article  PubMed  Google Scholar 

  67. Mohammed A, Gibbons LE, Gates G, Anderson ML, McCurry SM, McCormick W, Bowen JD, Grabowski TJ, Crane PK, Larson EB. Association of performance on dichotic auditory tests with risk for incident dementia and Alzheimer dementia. JAMA Otolaryngol Head Neck Surg 2022; 148(1): 20–27

    Article  PubMed  Google Scholar 

  68. Hwang PH, Longstreth WTJr, Thielke SM, Francis CE, Carone M, Kuller LH, Fitzpatrick AL. Longitudinal changes in hearing and visual impairments and risk of dementia in older adults in the United States. JAMA Netw Open 2022; 5(5): e2210734

    Article  PubMed  PubMed Central  Google Scholar 

  69. Hou K, Wu ZX, Chen XY, Wang JQ, Zhang D, Xiao C, Zhu D, Koya JB, Wei L, Li J, Chen ZS. Microbiota in health and diseases. Signal Transduct Target Ther 2022; 7(1): 135

    Article  PubMed  PubMed Central  Google Scholar 

  70. Megur A, Baltriukienė D, Bukelskienė V, Burokas A. The microbiota–gut–brain axis and Alzheimer’s disease: neuroinflammation is to blame? Nutrients 2020; 13(1): 37

    Article  PubMed  PubMed Central  Google Scholar 

  71. Vogt NM, Kerby RL, Dill-McFarland KA, Harding SJ, Merluzzi AP, Johnson SC, Carlsson CM, Asthana S, Zetterberg H, Blennow K, Bendlin BB, Rey FE. Gut microbiome alterations in Alzheimer’s disease. Sci Rep 2017; 7(1): 13537

    Article  PubMed  PubMed Central  Google Scholar 

  72. Bello-Medina PC, Corona-Cervantes K, Zavala Torres NG, González A, Pérez-Morales M, González-Franco DA, Gómez A, García-Mena J, Díaz-Cintra S, Pacheco-López G. Chronic-antibiotics induced gut microbiota dysbiosis rescues memory impairment and reduces β-amyloid aggregation in a preclinical Alzheimer’s disease model. Int J Mol Sci 2022; 23(15): 8209

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Tian Q, Studenski SA, An Y, Kuo PL, Schrack JA, Wanigatunga AA, Simonsick EM, Resnick SM, Ferrucci L. Association of combined slow gait and low activity fragmentation with later onset of cognitive impairment. JAMA Netw Open 2021; 4(11): e2135168

    Article  PubMed  PubMed Central  Google Scholar 

  74. Skillbäck T, Blennow K, Zetterberg H, Skoog J, Rydén L, Wetterberg H, Guo X, Sacuiu S, Mielke MM, Zettergren A, Skoog I, Kern S. Slowing gait speed precedes cognitive decline by several years. Alzheimers Dement 2022; 18(9): 1667–1676

    Article  PubMed  Google Scholar 

  75. Li P, Yu L, Lim ASP, Buchman AS, Scheer FAJL, Shea SA, Schneider JA, Bennett DA, Hu K. Fractal regulation and incident Alzheimer’s disease in elderly individuals. Alzheimers Dement 2018; 14(9): 1114–1125

    Article  PubMed  Google Scholar 

  76. Hiller AJ, Ishii M. Disorders of body weight, sleep and circadian rhythm as manifestations of hypothalamic dysfunction in Alzheimer’s disease. Front Cell Neurosci 2018; 12: 471

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Purnell C, Gao S, Callahan CM, Hendrie HC. Cardiovascular risk factors and incident Alzheimer disease: a systematic review of the literature. Alzheimer Dis Assoc Disord 2009; 23(1): 1–10

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Turana Y, Tengkawan J, Chia YC, Hoshide S, Shin J, Chen CH, Buranakitjaroen P, Nailes J, Park S, Siddique S, Sison J, Ann Soenarta A, Chin Tay J, Sogunuru GP, Zhang Y, Wang JG, Kario K. Hypertension and dementia: a comprehensive review from the HOPE Asia Network. J Clin Hypertens (Greenwich) 2019; 21(8): 1091–1098

    Article  PubMed  Google Scholar 

  79. Köbe T, Binette AP, Vogel JW, Meyer PF, Breitner JCS, Poirier J, Villeneuve S; Presymptomatic Evaluation of Novel or Experimental Treatments for Alzheimer Disease (PREVENTAD) Research Group. Vascular risk factors are associated with a decline in resting-state functional connectivity in cognitively unimpaired individuals at risk for Alzheimer’s disease: vascular risk factors and functional connectivity changes. Neuroimage 2021; 231: 117832

    Article  PubMed  Google Scholar 

  80. de Heus RAA, Tzourio C, Lee EJL, Opozda M, Vincent AD, Anstey KJ, Hofman A, Kario K, Lattanzi S, Launer LJ, Ma Y, Mahajan R, Mooijaart SP, Nagai M, Peters R, Turnbull D, Yano Y; VARIABLE BRAIN Consortium; Claassen JAHR, Tully PJ. Association between blood pressure variability with dementia and cognitive impairment: a systematic review and meta-analysis. Hypertension 2021; 78(5): 1478–1489

    Article  CAS  PubMed  Google Scholar 

  81. Sabbagh MN, Boada M, Borson S, Doraiswamy PM, Dubois B, Ingram J, Iwata A, Porsteinsson AP, Possin KL, Rabinovici GD, Vellas B, Chao S, Vergallo A, Hampel H. Early detection of mild cognitive impairment (MCI) in an at-home setting. J Prev Alzheimers Dis 2020; 7(3): 171–178

    CAS  PubMed  Google Scholar 

  82. Gordon BA, Blazey TM, Su Y, Hari-Raj A, Dincer A, Flores S, Christensen J, McDade E, Wang G, Xiong C, Cairns NJ, Hassenstab J, Marcus DS, Fagan AM, Jack CRJr, Hornbeck RC, Paumier KL, Ances BM, Berman SB, Brickman AM, Cash DM, Chhatwal JP, Correia S, Förster S, Fox NC, Graff-Radford NR, la Fougère C, Levin J, Masters CL, Rossor MN, Salloway S, Saykin AJ, Schofield PR, Thompson PM, Weiner MM, Holtzman DM, Raichle ME, Morris JC, Bateman RJ, Benzinger TLS. Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer’s disease: a longitudinal study. Lancet Neurol 2018; 17(3): 241–250

    Article  PubMed  PubMed Central  Google Scholar 

  83. Xiao H, Choi SR, Zhao R, Ploessl K, Alexoff D, Zhu L, Zha Z, Kung HF. A new highly deuterated [18F]AV-45, [18F]D15FSP, for imaging β-amyloid plaques in the brain. ACS Med Chem Lett 2021; 12(7): 1086–1092

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Grimmer T, Shi K, Diehl-Schmid J, Natale B, Drzezga A, Förster S, Förstl H, Schwaiger M, Yakushev I, Wester HJ, Kurz A, Yousefi BH. 18F-FIBT may expand PET for β-amyloid imaging in neurodegenerative diseases. Mol Psychiatry 2020; 25(10): 2608–2619

    Article  CAS  PubMed  Google Scholar 

  85. Tian M, Zuo C, Civelek AC, Carrio I, Watanabe Y, Kang KW, Murakami K, Garibotto V, Prior JO, Barthel H, Guan Y, Lu J, Zhou R, Jin C, Wu S, Zhang X, Zhong Y, Zhang H; Molecular Imaging-Based Precision Medicine Task Group of A3 (China-Japan-Korea) Foresight Program. International Nuclear Medicine Consensus on the Clinical Use of Amyloid Positron Emission Tomography in Alzheimer’s Disease. Phenomics 2022; 3(4): 375–389

    Article  PubMed  PubMed Central  Google Scholar 

  86. Wang X, Huang W, Su L, Xing Y, Jessen F, Sun Y, Shu N, Han Y. Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer’s disease. Mol Neurodegener 2020; 15(1): 55

    Article  PubMed  PubMed Central  Google Scholar 

  87. Viejo L, Noori A, Merrill E, Das S, Hyman BT, Serrano-Pozo A. Systematic review of human post-mortem immunohistochemical studies and bioinformatics analyses unveil the complexity of astrocyte reaction in Alzheimer’s disease. Neuropathol Appl Neurobiol 2022; 48(1): e12753

    Article  CAS  PubMed  Google Scholar 

  88. Shea D, Colasurdo E, Smith A, Paschall C, Jayadev S, Keene CD, Galasko D, Ko A, Li G, Peskind E, Daggett V. SOBA: development and testing of a soluble oligomer binding assay for detection of amyloidogenic toxic oligomers. Proc Natl Acad Sci USA 2022; 119(50): e2213157119

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Chatterjee P, Pedrini S, Doecke JD, Thota R, Villemagne VL, Doré V, Singh AK, Wang P, Rainey-Smith S, Fowler C, Taddei K, Sohrabi HR, Molloy MP, Ames D, Maruff P, Rowe CC, Masters CL, Martins RN; AIBL Research Group. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer’s disease continuum: a cross-sectional and longitudinal study in the AIBL cohort. Alzheimers Dement 2023; 19(4): 1117–1134

    Article  CAS  PubMed  Google Scholar 

  90. Lee YJ, Lin SY, Peng SW, Lin YC, Chen TB, Wang PN, Cheng IH. Predictive utility of plasma amyloid and tau for cognitive decline in cognitively normal adults. J Prev Alzheimers Dis 2023; 10(2): 178–185

    PubMed  Google Scholar 

  91. Bellaver B, Povala G, Ferreira PCL, Ferrari-Souza JP, Leffa DT, Lussier FZ, Benedet AL, Ashton NJ, Triana-Baltzer G, Kolb HC, Tissot C, Therriault J, Servaes S, Stevenson J, Rahmouni N, Lopez OL, Tudorascu DL, Villemagne VL, Ikonomovic MD, Gauthier S, Zimmer ER, Zetterberg H, Blennow K, Aizenstein HJ, Klunk WE, Snitz BE, Maki P, Thurston RC, Cohen AD, Ganguli M, Karikari TK, Rosa-Neto P, Pascoal TA. Astrocyte reactivity influences amyloid-β effects on tau pathology in preclinical Alzheimer’s disease. Nat Med 2023; 29(7): 1775–1781

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Rajan KB, Aggarwal NT, McAninch EA, Weuve J, Barnes LL, Wilson RS, DeCarli C, Evans DA. Remote blood biomarkers of longitudinal cognitive outcomes in a population study. Ann Neurol 2020; 88(6): 1065–1076

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Husain M. Blood tests to screen for Alzheimer’s disease. Brain 2021; 144(2): 355–356

    Article  PubMed  Google Scholar 

  94. Mattsson-Carlgren N, Salvadó G, Ashton NJ, Tideman P, Stomrud E, Zetterberg H, Ossenkoppele R, Betthauser TJ, Cody KA, Jonaitis EM, Langhough R, Palmqvist S, Blennow K, Janelidze S, Johnson SC, Hansson O. Prediction of longitudinal cognitive decline in preclinical alzheimer disease using plasma biomarkers. JAMA Neurol 2023; 80(4): 360–369

    Article  PubMed  PubMed Central  Google Scholar 

  95. Pascoal TA, Benedet AL, Ashton NJ, Kang MS, Therriault J, Chamoun M, Savard M, Lussier FZ, Tissot C, Karikari TK, Ottoy J, Mathotaarachchi S, Stevenson J, Massarweh G, Schöll M, de Leon MJ, Soucy JP, Edison P, Blennow K, Zetterberg H, Gauthier S, Rosa-Neto P. Microglial activation and tau propagate jointly across Braak stages. Nat Med 2021; 27(9): 1592–1599

    Article  CAS  PubMed  Google Scholar 

  96. Johansson C, Thordardottir S, Laffita-Mesa J, Rodriguez-Vieitez E, Zetterberg H, Blennow K, Graff C. Plasma biomarker profiles in autosomal dominant Alzheimer’s disease. Brain 2023; 146(3): 1132–1140

    Article  PubMed  PubMed Central  Google Scholar 

  97. Teunissen CE, Verberk IMW, Thijssen EH, Vermunt L, Hansson O, Zetterberg H, van der Flier WM, Mielke MM, Del Campo M. Blood-based biomarkers for Alzheimer’s disease: towards clinical implementation. Lancet Neurol 2022; 21(1): 66–77

    Article  CAS  PubMed  Google Scholar 

  98. Olsson B, Lautner R, Andreasson U, Öhrfelt A, Portelius E, Bjerke M, Hölttä M, Rosén C, Olsson C, Strobel G, Wu E, Dakin K, Petzold M, Blennow K, Zetterberg H. CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis. Lancet Neurol 2016; 15(7): 673–684

    Article  CAS  PubMed  Google Scholar 

  99. Ryan D, Robards K. Metabolomics: the greatest omics of them all? Anal Chem 2006; 78(23): 7954–7958

    Article  CAS  PubMed  Google Scholar 

  100. Johnson ECB, Dammer EB, Duong DM, Ping L, Zhou M, Yin L, Higginbotham LA, Guajardo A, White B, Troncoso JC, Thambisetty M, Montine TJ, Lee EB, Trojanowski JQ, Beach TG, Reiman EM, Haroutunian V, Wang M, Schadt E, Zhang B, Dickson DW, Ertekin-Taner N, Golde TE, Petyuk VA, De Jager PL, Bennett DA, Wingo TS, Rangaraju S, Hajjar I, Shulman JM, Lah JJ, Levey AI, Seyfried NT. Large-scale proteomic analysis of Alzheimer’s disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation. Nat Med 2020; 26(5): 769–780

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. Sriwichaiin S, Chattipakorn N, Chattipakorn SC. Metabolomic alterations in the blood and brain in association with Alzheimer’s disease: evidence from in vivo to clinical studies. J Alzheimers Dis 2021; 84(1): 23–50

    Article  CAS  PubMed  Google Scholar 

  102. Sakr F, Dyrba M, Brauer A, Teipel S; Alzheimer’s Disease Neuroimaging Initiative. Association of lipidomics signatures in blood with clinical progression in preclinical and prodromal Alzheimer’s disease. J Alzheimers Dis 2022; 85: 1115–1127

    Article  CAS  PubMed  Google Scholar 

  103. Casas-Fernández E, Peña-Bautista C, Baquero M, Cháfer-Pericás C. Lipids as early and minimally invasive biomarkers for Alzheimer’s disease. Curr Neuropharmacol 2022; 20(8): 1613–1631

    Article  PubMed  PubMed Central  Google Scholar 

  104. Zheng Y, Xu Q, Jin Q, Du Y, Yan J, Gao H, Zheng H. Urinary and faecal metabolic characteristics in APP/PS1 transgenic mouse model of Alzheimer’s disease with and without cognitive decline. Biochem Biophys Res Commun 2022; 604: 130–136

    Article  CAS  PubMed  Google Scholar 

  105. Shao H, Im H, Castro CM, Breakefield X, Weissleder R, Lee H. New technologies for analysis of extracellular vesicles. Chem Rev 2018; 118(4): 1917–1950

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. Hamlett ED, Ledreux A, Potter H, Chial HJ, Patterson D, Espinosa JM, Bettcher BM, Granholm AC. Exosomal biomarkers in Down syndrome and Alzheimer’s disease. Free Radic Biol Med 2018; 114: 110–121

    Article  CAS  PubMed  Google Scholar 

  107. Jia L, Qiu Q, Zhang H, Chu L, Du Y, Zhang J, Zhou C, Liang F, Shi S, Wang S, Qin W, Wang Q, Li F, Wang Q, Li Y, Shen L, Wei Y, Jia J. Concordance between the assessment of Aβ42, T-tau, and P-T181-tau in peripheral blood neuronal-derived exosomes and cerebrospinal fluid. Alzheimers Dement 2019; 15(8): 1071–1080

    Article  PubMed  Google Scholar 

  108. Jia L, Zhu M, Yang J, Pang Y, Wang Q, Li T, Li F, Wang Q, Li Y, Wei Y. Exosomal microRNA-based predictive model for preclinical Alzheimer’s disease: a multicenter study. Biol Psychiatry 2022; 92(1): 44–53

    Article  CAS  PubMed  Google Scholar 

  109. Naughton SX, Raval U, Pasinetti GM. The viral hypothesis in Alzheimer’s disease: novel insights and pathogen-based biomarkers. J Pers Med 2020; 10(3): 74

    Article  PubMed  PubMed Central  Google Scholar 

  110. Seaks CE, Wilcock DM. Infectious hypothesis of Alzheimer disease. PLoS Pathog 2020; 16(11): e1008596

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  111. Pastore A, Raimondi F, Rajendran L, Temussi PA. Why does the Aβ peptide of Alzheimer share structural similarity with antimicrobial peptides? Commun Biol 2020; 3(1): 135

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  112. French PW. Unfolded p53 in non-neuronal cells supports bacterial etiology of Alzheimer’s disease. Neural Regen Res 2022; 17(12): 2619–2622

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  113. Ishii M, Iadecola C. Metabolic and non-cognitive manifestations of Alzheimer’s disease: the hypothalamus as both culprit and target of pathology. Cell Metab 2015; 22(5): 761–776

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  114. Ghosh A. Endocrine, metabolic, nutritional, and toxic disorders leading to dementia. Ann Indian Acad Neurol 2010; 13(Suppl 2): S63–S68

    Article  PubMed  PubMed Central  Google Scholar 

  115. Berlanga-Acosta J, Guillén-Nieto G, Rodríguez-Rodríguez N, Bringas-Vega ML, García-Del-Barco-Herrera D, Berlanga-Saez JO, García-Ojalvo A, Valdés-Sosa MJ, Valdés-Sosa PA. Insulin resistance at the crossroad of Alzheimer disease pathology: a review. Front Endocrinol (Lausanne) 2020; 11: 560375

    Article  PubMed  Google Scholar 

  116. Zhou C, Dong C, Xie Z, Hao W, Fu C, Sun H, Zhu D. Sex-specific associations between diabetes and dementia: the role of age at onset of disease, insulin use and complications. Biol Sex Differ 2023; 14(1): 9

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  117. Ennis GE, An Y, Resnick SM, Ferrucci L, O’Brien RJ, Moffat SD. Long-term cortisol measures predict Alzheimer disease risk. Neurology 2017; 88(4): 371–378

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  118. Ouanes S, Popp J. High cortisol and the risk of dementia and Alzheimer’s disease: a review of the literature. Front Aging Neurosci 2019; 11: 43

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  119. Udeh-Momoh CT, Su B, Evans S, Zheng B, Sindi S, Tzoulaki I, Perneczky R, Middleton LT; Alzheimer’s Disease Neuroimaging Initiative. Cortisol, amyloid-β, and reserve predicts Alzheimer’s disease progression for cognitively normal older adults. J Alzheimers Dis 2019; 70(2): 553–562

    Article  PubMed  Google Scholar 

  120. Li H, Chen K, Yang L, Wang Q, Zhang J, He J. The role of plasma cortisol in dementia, epilepsy, and multiple sclerosis: a Mendelian randomization study. Front Endocrinol (Lausanne) 2023; 14: 1107780

    Article  PubMed  Google Scholar 

  121. Tan ZS, Beiser A, Vasan RS, Au R, Auerbach S, Kiel DP, Wolf PA, Seshadri S. Thyroid function and the risk of Alzheimer disease: the Framingham Study. Arch Intern Med 2008; 168(14): 1514–1520

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  122. Marriott RJ, Murray K, Flicker L, Hankey GJ, Matsumoto AM, Dwivedi G, Antonio L, Almeida OP, Bhasin S, Dobs AS, Handelsman DJ, Haring R, O’Neill TW, Ohlsson C, Orwoll ES, Vanderschueren D, Wittert GA, Wu FCW, Yeap BB. Lower serum testosterone concentrations are associated with a higher incidence of dementia in men: the UK Biobank prospective cohort study. Alzheimers Dement 2022; 18(10): 1907–1918

    Article  CAS  PubMed  Google Scholar 

  123. Keyvani K, Münster Y, Kurapati NK, Rubach S, Schönborn A, Kocakavuk E, Karout M, Hammesfahr P, Wang YC, Hermann DM, Teuber-Hanselmann S, Herring A. Higher levels of kallikrein-8 in female brain may increase the risk for Alzheimer’s disease. Brain Pathol 2018; 28(6): 947–964

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  124. Azocar I, Rapaport P, Burton A, Meisel G, Orgeta V. Risk factors for apathy in Alzheimer’s disease: a systematic review of longitudinal evidence. Ageing Res Rev 2022; 79: 101672

    Article  PubMed  Google Scholar 

  125. Ng KP, Chiew H, Rosa-Neto P, Kandiah N, Ismail Z, Gauthier S. Associations of AT(N) biomarkers with neuropsychiatric symptoms in preclinical Alzheimer’s disease and cognitively unimpaired individuals. Transl Neurodegener 2021; 10(1): 11

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  126. Mosaferi B, Jand Y, Salari AA. Gut microbiota depletion from early adolescence alters anxiety and depression-related behaviours in male mice with Alzheimer-like disease. Sci Rep 2021; 11(1): 22941

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  127. He C, Hu Z, Jiang C. Sleep disturbance: an early sign of Alzheimer’s disease. Neurosci Bull 2020; 36(4): 449–451

    Article  PubMed  Google Scholar 

  128. Xiong X, Hu T, Yin Z, Zhang Y, Chen F, Lei P. Research advances in the study of sleep disorders, circadian rhythm disturbances and Alzheimer’s disease. Front Aging Neurosci 2022; 14: 944283

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  129. Oh JY, Walsh CM, Ranasinghe K, Mladinov M, Pereira FL, Petersen C, Falgàs N, Yack L, Lamore T, Nasar R, Lew C, Li S, Metzler T, Coppola Q, Pandher N, Le M, Heuer HW, Heinsen H, Spina S, Seeley WW, Kramer J, Rabinovici GD, Boxer AL, Miller BL, Vossel K, Neylan TC, Grinberg LT. Subcortical neuronal correlates of sleep in neurodegenerative diseases. JAMA Neurol 2022; 79(5): 498–508

    Article  PubMed  PubMed Central  Google Scholar 

  130. Lew CH, Petersen C, Neylan TC, Grinberg LT. Tau-driven degeneration of sleep- and wake-regulating neurons in Alzheimer’s disease. Sleep Med Rev 2021; 60: 101541

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  131. Kang SS, Meng L, Zhang X, Wu Z, Mancieri A, Xie B, Liu X, Weinshenker D, Peng J, Zhang Z, Ye K. Tau modification by the norepinephrine metabolite DOPEGAL stimulates its pathology and propagation. Nat Struct Mol Biol 2022; 29(4): 292–305

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  132. Guo Y, Li S, Zeng LH, Tan J. Tau-targeting therapy in Alzheimer’s disease: critical advances and future opportunities. Ageing Neur Dis 2022; 2: 11

    Article  CAS  Google Scholar 

  133. Hernández-Soto R, Rojas-García KD, Peña-Ortega F. Sudden intrabulbar amyloid increase simultaneously disrupts olfactory bulb oscillations and odor detection. Neural Plast 2019; 2019: 3424906

    Article  PubMed  PubMed Central  Google Scholar 

  134. López-de-Eguileta A, López-García S, Lage C, Pozueta A, García-Martínez M, Kazimierczak M, Bravo M, Irure J, López-Hoyos M, Muñoz-Cacho P, Rodríguez-Perez N, Tordesillas-Gutiérrez D, Goikoetxea A, Nebot C, Rodríguez-Rodríguez E, Casado A, Sánchez-Juan P. The retinal ganglion cell layer reflects neurodegenerative changes in cognitively unimpaired individuals. Alzheimers Res Ther 2022; 14(1): 57

    Article  PubMed  PubMed Central  Google Scholar 

  135. Bartley SC, Proctor MT, Xia H, Ho E, Kang DS, Schuster K, Bicca MA, Seckler HS, Viola KL, Patrie SM, Kelleher NL, De Mello FG, Klein WL. An essential role for Alzheimer’s-linked amyloid beta oligomers in neurodevelopment: transient expression of multiple proteoforms during retina histogenesis. Int J Mol Sci 2022; 23(4): 2208

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  136. Habiba U, Morley J, Krockenberger M, Summers BA, Tayebi M. A sequential deposition of amyloid beta oligomers, plaques and phosphorylated tau occurs throughout life in the canine retina. Ageing Neur Dis 2022; 2: 7

    Article  CAS  Google Scholar 

  137. Gupta VB, Chitranshi N, den Haan J, Mirzaei M, You Y, Lim JK, Basavarajappa D, Godinez A, Di Angelantonio S, Sachdev P, Salekdeh GH, Bouwman F, Graham S, Gupta V. Retinal changes in Alzheimer’s disease—integrated prospects of imaging, functional and molecular advances. Prog Retin Eye Res 2021; 82: 100899

    Article  CAS  PubMed  Google Scholar 

  138. Chang M, Kim HJ, Mook-Jung I, Oh SH. Hearing loss as a risk factor for cognitive impairment and loss of synapses in the hippocampus. Behav Brain Res 2019; 372: 112069

    Article  PubMed  Google Scholar 

  139. Brenowitz WD, Filshtein TJ, Yaffe K, Walter S, Ackley SF, Hoffmann TJ, Jorgenson E, Whitmer RA, Glymour MM. Association of genetic risk for Alzheimer disease and hearing impairment. Neurology 2020; 95(16): e2225–e2234

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  140. Abdulrahman H, van Dalen JW, den Brok M, Latimer CS, Larson EB, Richard E. Hypertension and Alzheimer’s disease pathology at autopsy: a systematic review. Alzheimers Dement 2022; 18(11): 2308–2326

    Article  CAS  PubMed  Google Scholar 

  141. Hu X, Wang T, Jin F. Alzheimer’s disease and gut microbiota. Sci China Life Sci 2016; 59(10): 1006–1023

    Article  CAS  PubMed  Google Scholar 

  142. van de Wouw M, Boehme M, Lyte JM, Wiley N, Strain C, O’Sullivan O, Clarke G, Stanton C, Dinan TG, Cryan JF. Short-chain fatty acids: microbial metabolites that alleviate stress-induced brain-gut axis alterations. J Physiol 2018; 596(20): 4923–4944

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  143. Gonzalez-Escamilla G, Atienza M, Garcia-Solis D, Cantero JL. Cerebral and blood correlates of reduced functional connectivity in mild cognitive impairment. Brain Struct Funct 2016; 221(1): 631–645

    Article  CAS  PubMed  Google Scholar 

  144. Muurling M, Rhodius-Meester HFM, Pärkkä J, van Gils M, Frederiksen KS, Bruun M, Hasselbalch SG, Soininen H, Herukka SK, Hallikainen M, Teunissen CE, Visser PJ, Scheltens P, van der Flier WM, Mattila J, Lötjönen J, de Boer C. Gait disturbances are associated with increased cognitive impairment and cerebrospinal fluid tau levels in a memory clinic cohort. J Alzheimers Dis 2020; 76(3): 1061–1070

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This review work was supported by funding from the National Natural Science Foundation of China (Nos. 32220103006 and 82271524) and the Intramural Research Program of NIH, National Institute on Aging (Nos. ZIA AG000944 and AG000928).

Author information

Author notes

  1. Yixin Chen and Murad Al-Nusaif equally contributed to this work.

Authors and Affiliations

  1. Liaoning Provincial Key Laboratory for Research on the Pathogenic Mechanisms of Neurological Diseases, The First Affiliated Hospital of Dalian Medical University, Dalian, 116021, China

    Yixin Chen, Murad Al-Nusaif, Song Li, Xiang Tan, Huijia Yang & Weidong Le

  2. Transgenic Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, 20892, USA

    Huaibin Cai

  3. Institute of Neurology, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, 610072, China

    Weidong Le

Authors
  1. Yixin Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Murad Al-Nusaif
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Song Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xiang Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Huijia Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Huaibin Cai
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Weidong Le
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Weidong Le.

Ethics declarations

Conflicts of interest Yixin Chen, Murad Al-Nusaif, Song Li, Xiang Tan, Huijia Yang, Huaibin Cai, and Weidong Le declare that they have no competing interests.

This manuscript is a review article and does not involve a research protocol requiring approval by the relevant institutional review board or ethics committee.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chen, Y., Al-Nusaif, M., Li, S. et al. Progress on early diagnosing Alzheimer’s disease. Front. Med. (2024). https://doi.org/10.1007/s11684-023-1047-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11684-023-1047-1

Keywords

Search

Navigation